7 billion medical insurance products, exclusive formulations approved

Medical Network
reported on March 19 that there are 7 billion medical insurance products, exclusive dosage forms have been approved
, and exclusive dosage forms have been approved.
Recently, Poinsettia issued an announcement stating that its wholly-owned subsidiary Guangzhou Poinsettia Pharmaceuticals’ ambroxol hydrochloride drops have been approved for production.
This product is a domestic exclusive formulation
.
Ambroxol is a very classic and commonly used expectorant in clinical practice.
It has the properties of promoting mucus elimination and dissolving secretions.
It can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, thereby promoting sputum and improving respiratory conditions.
, The application history is more than 40 years
.
In recent years, the sales of ambroxol have declined, but the decline is not large, relatively stable, and still maintained at a high level
.
According to data from Mi Nei.
com, the sales of terminal ambroxol in China's public medical institutions exceeded 7 billion yuan in 2019
.


(Data source: Mi Nei.
com) Ambroxol hydrochloride includes various dosage forms such as oral solution, tablets, and injections
.
At present, 6 products have been evaluated, including ambroxol hydrochloride drops, ambroxol hydrochloride dispersible tablets, ambroxol hydrochloride capsules, ambroxol hydrochloride injection, ambroxol hydrochloride tablets, and ambroxol hydrochloride atomized inhalation Solution
.
It is worth noting that oral solid preparations are the third batch of nationally sourced varieties, and the winning price of 30mg is less than 1 cent for a single tablet; injections are the fourth batch of collectively-sourced varieties, and the lowest winning price for a single unit is 2 cents and 3 cents; As for inhalants, 2 companies have been reviewed, and several acceptance numbers are still under review.
After the three companies are assembled, they may enter the next batch of collective procurement lists
.
At present, only two companies , namely Poinsettia and Baoding Aihui Pharmaceutical, have submitted a listing application for ambroxol drops.
Poinsettia has been approved as an exclusive product with early application and early approval
.
At present, drops are also covered by medical insurance.
With exclusive dosage forms and ultra-low prices of other mainstream dosage forms, the market prospects are exciting
.
According to data from Minai.
com, the original research manufacturer Boehringer Ingelheim ranked first with a market share of 18.
76%.
Poinsettia had no outstanding performance in the related drug market before, but this situation is likely to be broken in the future
.
(Data source: Mi Nei.
com) The
　　children's medicine market has broad prospects.

Exclusive formulations.
Since there are no competing products of the same variety and different manufacturers, a good price system can be maintained, and a virtuous cycle of prices can be formed in the bidding .
In addition, there will be no similar competition in market development.
Opponent
.
The market prospects of ambroxol hydrochloride drops are therefore highly anticipated, but in addition, it is worth noting that ambroxol hydrochloride drops are suitable for people including young children, and the instructions indicate clear usage and dosage for children
.
In fact, children’s medicine has always been an important part of the poinsettia product line.
The acquisition of the registration certificate for ambroxol hydrochloride drops will also further enrich the pipeline and categories of poinsettia children’s medicine products, enhance the company’s competitiveness in the field of children’s medicine, and benefit the company.
The performance has a positive impact
.
In China, children's medicines refer to special medicines used by minors under the age of 14, including special medicines specifically for children or medicines whose usage and dosage are indicated in the drug inserts
.
Statistics show that at the end of 2019, the national population under 15 (including 15 years old) was 249 million people, accounting for 17.
8% of the total population, and the annual number of outpatient visits for children in China exceeded 200 million.
Therefore, the market for high-quality children's medicine products has huge room for growth
.
However, the development of China's children's market is still immature
.
Child-specific medicines less kind, less dosage, low dosage strengths, and more generic drugs, adverse reactions multi
.
For a long time, there has been a situation of "medicine by breaking, metering by guessing", and there are still great hidden dangers in the safety of children's medication
.
In addition pediatric medicines taste bad, poor medication compliance
.
In recent years, the state has also attached great importance to the field of children’s medicine.
The "Several Opinions on Guaranteeing Children’s Drug Use", "Opinions on Strengthening the Reform and Development of Children’s Medical and Health Services" and other relevant documents have regulated the market situation of children’s medicines and supported children’s medicines.
Market development
.
At present, the industry is paying more and more attention to children's medicines, and the awareness of children's medicines is constantly improving, and many companies have deployed one after another
.
According to data from the Southern Institute of Pharmaceutical Economics, China's children's medicine market exceeded 150 billion yuan in 2019, and the growth rate is higher than the overall growth rate of the pharmaceutical industry
.
However, the proportion of the children's medicine market is much lower than the proportion of children in the total population.
It can be seen that China's children's medicine market still has a huge market prospect, and the industry is still in a period of promising strategic opportunities
.
As the country pays more attention to the growth of children, and the awareness of the society and the family to regulate the use of drugs, the scale of the children's drug market will gradually increase
.